from 14/11/13 investor presentation - page 12 - couple expire this year so wondering how important they are in the scheme of things!
page 16 and other presentations refer to Hexima collaboration - which had at that stage from what I understand common officeholders (but common officeholder resigned from one position since that time) and the J/V? was subsequently cancelled but for some reason I am unable to locate anything to do with who ended up with the IP, how much ACR had "invested" in it, and whether ACR was reimbursed in any way for its input or why ACR did not end up with the IP!! wonder what went on with this? - if anyone has any details would love to know as it was our funds that funded some portion of it all!!!
PATENT PROTECTION IN UNITED STATES
12
Formulation and delivery system
4 granted patents, expiry 2017
Underarm administration
1 granted patent, expiry 2027
1 allowed patent, expiry 2026
1 patent application pending
Applicator
2 granted patents, expiry 2026 and 2030
1 patent application pending
Add to My Watchlist
What is My Watchlist?
